OphRx Overview

OphRx is developing eye drops based on noninvasive drug delivery that utilize lyotropic liquid crystals as an alternative to current delivery modalities, such as intra-vitreal injections, used to treat diseases at the back of the eye. This platform technology can also be used for front-of-the-eye treatments.
OphRx is currently in the preclinical stage of development of two product candidates: OPH-101, an alternative topical treatment to intravitreal injections for wet AMD; and OPH-100, a treatment for DES.
OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.

Cumulative Funding Raised Over Time ($)

Employees Over Time

BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert

#Customers

When size matters: Tiny innovations for a better world

#Investment

Conference to showcase Hebrew University nanotech

#Partners #Investment

Bio Light's IOPtiMate[TM] System Receives Regulatory Approval in Canada

#Customers

Companies you might be interested in

Driven by Finder AI

Eximore
Ophthalmic Drug Delivery

1-10 employees • Funding Stage: A

shared sectors

Drug Delivery

Also shared

ophthalmology eye-diseases drug-delivery glaucoma medical-technologies clinics non-invasive

Are these companies similar?
GentaGel
Slow-release Antibiotic Treatment

1-10 employees • Funding Stage: Pre-Funding

shared sectors

Drug Delivery

Also shared

pharmaceuticals

Are these companies similar?
Pharmmies
Precise Dosages Pharmaceutical Gummies

1-10 employees • Funding Stage: Pre-Funding

shared sectors

Drug Delivery

Also shared

drug-delivery

Are these companies similar?
Hopec Pharma
Immunotherapy Treatment for Bladder Cancer

1-10 employees • Funding Stage: Seed

shared sectors

Pharma & Medical Biotechnology

Also shared

pharmaceuticals

Are these companies similar?